Brief: Vivos Inc. Announces Progress Toward FDA Investigational Device Exemption (Ide) Submission
10/02/2026 13:42
Feb 10 (Reuters) - Vivos Inc RDGL.PK: VIVOS INC. ANNOUNCES SIGNIFICANT PROGRESS TOWARD FDA INVESTIGATIONAL DEVICE EXEMPTION (IDE) SUBMISSION FOR RADIOGEL® PRECISION RADIONUCLIDE THERAPY™ Source text: ID:nGNX1TG8Jf Further company coverage: RDGL.PK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vivos
See all newsBrief: Vivos Inc. Announces Progress Toward FDA Investigational Device Exemption (Ide) Submission
Brief: Vivos Inc. Strengthens Strategic Collaboration With Exubrion Therapeutics
Brief: Vivos Inc. Retains Top FDA Regulatory Expert Dr. John J. Smith, M.D., J.D., To Support Ide Submission For Radiogel®
Brief: Vivos Board Authorizes To Establish A Corporate Entity In India
Brief: Vivos Inc. Achieves Record Growth In IsoPet® Animal Cancer Treatments In Q1 2025